Adjuvant therapy after radical prostatectomy: Clinical considerations

Surgical Oncology

Volumn 18, Issue 3, 2009, Pages 247-254

  Mitra, A ^a   Khoo, V ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Androgen Deprivation; Chemotherapy; Prostate cancer; PSA; Radiotherapy; Salvage

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; HUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 68849089693     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2009.02.005     Document Type: Review

References (53)

1. Han K.R., Cohen J.K., Miller R.J., et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol 170 (2003) 1126-1130
2. Djavan B., Moul J.W., Zlotta A., et al. PSA progression following radical prostatectomy and radiation therapy: new standards in the new millennium. Eur Urol 43 (2003) 12-27
3. Swindle P.W., Kattan M.W., and Scardino P.T. Markers and meaning of primary treatment failure. Urol Clin North Am 30 (2003) 377-401
4. Walsh P.C., Oesterling J.E., Epstein J.I., et al. The value of prostate-specific antigen in the management of localized prostatic cancer. Prog Clin Biol Res 303 (1989) 27-33
5. Zincke H., Oesterling J.E., Blute M.L., et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152 (1994) 1850-1857
6. Amling C.L., Bergstralh E.J., Blute M.L., et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146-1151
7. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61 (2003) 365-369
8. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
9. Ward J.F., Blute M.L., Slezak J., et al. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol 170 (2003) 1872-1876
10. Boccon-Gibod L., Djavan W.B., Hammerer P., et al. Management of prostate-specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 58 (2004) 382-390
11. Song D.Y., Thompson T.L., Ramakrishnan V., et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 60 (2002) 281-287
12. Albertsen P.C., Hanley J.A., Gleason D.F., and Barry M.J. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 280 (1998) 975-980
13. Albertsen P.C., Hanley J.A., and Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095-2101
14. Chodak G.W., Thisted R.A., Gerber G.S., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 (1994) 242-248
15. Johansson J.E., Holmberg L., Johansson S., et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277 (1997) 467-471
16. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
17. Lotan Y., Shariat S.F., Khoddami S.M., et al. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. J Urol 171 (2004) 2209-2214
18. Briganti A., Karakiewicz P.I., Chun F.K., et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 51 (2007) 1573-1581
19. Grossfeld G.D., Latini D.M., Lubeck D.P., et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 169 (2003) 157-163
20. Philip J., Ragavan N., Desouza J., et al. Effect of peripheral biopsies in maximising early prostate cancer detection in 8-, 10- or 12-core biopsy regimens. BJU Int 93 (2004) 1218-1220
21. Sengupta S., Blute M.L., Bagniewski S.M., et al. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 101 (2008) 170-174
22. van Oort I.M., Witjes J.A., Kok D.E., et al. The prognostic role of the pathological T2 subclassification for prostate cancer in the 2002 tumour-nodes-metastasis staging system. BJU Int 102 (2008) 438-441
23. Rodriguez-Covarrubias F., Larre S., De La Taille A., et al. The outcome of patients with pathological Gleason score ≥ 8 prostate cancer after radical prostatectomy. BJU Int 101 (2008) 305-307
24. Hernandez D.J., Nielsen M.E., Han M., et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology (2008)
25. Vickers A.J., Bianco F.J., Gonen M., et al. Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008)
26. Ward J.F., Slezak J.M., Blute M.L., et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751-756
27. Hsu C.Y., Joniau S., Oyen R., et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007) 121-128 [discussion 128-129]
28. Kattan M.W., Wheeler T.M., and Scardino P.T. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17 (1999) 1499-1507
29. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
30. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 166 (2001) 2185-2188
31. Gancarczyk K.J., Wu H., McLeod D.G., et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the center for prostate disease research nomograms. Urology 61 (2003) 589-595
32. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
33. Donohue J.F., Bianco Jr. F.J., Kuroiwa K., et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J Urol 176 (2006) 991-995
34. Eastham J.A., Kattan M.W., Riedel E., et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol 170 (2003) 2292-2295
35. Karakiewicz P.I., Eastham J.A., Graefen M., et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology 66 (2005) 1245-1250
36. Kausik S.J., Blute M.L., Sebo T.J., et al. Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer 95 (2002) 1215-1219
37. Vis A.N., Schroder F.H., and van der Kwast T.H. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 50 (2006) 258-265
38. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
39. Buskirk S.J., Pisansky T.M., Schild S.E., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176 (2006) 985-990
40. D'Amico A.V., Moul J., Carroll P.R., et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S46 [discussion S46-S47]
41. Pollack A., Zagars G.K., and Kavadi V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74 (1994) 670-678
42. Okotie O.T., Aronson W.J., Wieder J.A., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 (2004) 2260-2264
43. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
44. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
45. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
46. Denham J.W., Steigler A., Lamb D.S., et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6 (2005) 841-850
47. Katz M.S., Zelefsky M.J., Venkatraman E.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
48. King C.R., Presti Jr. J.C., Gill H., et al. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?. Int J Radiat Oncol Biol Phys 59 (2004) 341-347
49. Eulau S.M., Tate D.J., Stamey T.A., et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41 (1998) 735-740
50. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
51. Parker C., Clarke N., Logue J., et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Clin Oncol (R Coll Radiol) 19 (2007) 167-171
52. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
53. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456